Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
The latest announcement is out from Kuros Biosciences ( (CH:KURN) ).
Kuros Biosciences announced a 77% year-over-year increase in revenue for the first nine months of 2025, driven by strong sales of its MagnetOs products. The company has launched the MagnetOs MIS Delivery System in the U.S., following FDA clearance, and received approval for MagnetOs products in Saudi Arabia, marking significant milestones in its strategic expansion and positioning in the medical device industry.
The most recent analyst rating on (CH:KURN) stock is a Hold with a CHF25.00 price target. To see the full list of analyst forecasts on Kuros Biosciences stock, see the CH:KURN Stock Forecast page.
More about Kuros Biosciences
Kuros Biosciences is a leader in innovative biologic technologies, with operations in the United States, Switzerland, and the Netherlands. The company is listed on the SIX Swiss Exchange and focuses on developing advanced bone graft products, such as MagnetOs, which is used globally in various medical procedures.
Average Trading Volume: 223,493
Technical Sentiment Signal: Buy
Current Market Cap: CHF1.12B
Find detailed analytics on KURN stock on TipRanks’ Stock Analysis page.